Article

Daily administration of low-dose daunorubicin or doxorubicin inhibits hypoxia-inducible factor 1 and tumor vascularization

2022-06-17

Abstract excerpt

Using a hypoxia-inducible factor 1 (HIF-1)-dependent luciferase reporter in Hep3B human hepatocellular carcinoma cells, we screened over 3,000 drugs that have been used in clinical trials and identified multiple anthracyclines as inhibitors of HIF-1 activity. Anthracyclines interfered with the ability of HIF-1 to bind to DNA. Daily injection of tumor-bearing mice with anthracyclines at low dose inhibited expressio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 81d69fb1-4301-5812-bff6-14e0e9b9ce61
DOI: 10.1101/2022.06.15.492526

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 11 closest

Daily administration of low-dose daunorubicin or doxorubicin inhibits hypoxia-inducible factor 1 and tumor vascularizationDOI 10.1101/2022.06.15.492526Read

Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors.Semantic proximity Read

Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast CancerSemantic proximity Read

Analysis of Hypoxia-Related Gene Expression in Sarcomas and Effect of Hypoxia on RNA Interference of Vascular Endothelial Cell Growth Factor ASemantic proximity Read

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell CarcinomaSemantic proximity Read

Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D.Semantic proximity Read

Heterogeneous vascular dependence of tumor cell populations.Semantic proximity Read

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.Semantic proximity Read

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.Semantic proximity Read

Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.Semantic proximity Read

In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivoSemantic proximity Read

Hypoxia inducible factor-1α as a cancer drug targetSemantic proximity Read